Manufacturer
Novartis NDC Codes
Finished products listed with the FDA under labeler names that contain “Novartis”.
Most-listed names
By number of FDA listings (strengths, forms and packages), not by sales.
Products
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Adakveocrizanlizumab | Crizanlizumab 10 mg/mL | InjectionIntravenous | Novartis Pharmaceuticals Corporation | 0078-0883 |
| Afinitoreverolimus | Everolimus 5 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0566 |
| Afinitoreverolimus | Everolimus 10 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0567 |
| Afinitoreverolimus | Everolimus 2.5 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0594 |
| Afinitoreverolimus | Everolimus 7.5 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0620 |
| Afinitor Disperzeverolimus | Everolimus 2 mg/1 | Tablet, For suspensionOral | Novartis Pharmaceuticals Corporation | 0078-0626 |
| Afinitor Disperzeverolimus | Everolimus 3 mg/1 | Tablet, For suspensionOral | Novartis Pharmaceuticals Corporation | 0078-0627 |
| Afinitor Disperzeverolimus | Everolimus 5 mg/1 | Tablet, For suspensionOral | Novartis Pharmaceuticals Corporation | 0078-0628 |
| Beovubrolucizumab | Brolucizumab 6 mg/.05mL | Injection, SolutionIntravitreal | Novartis Pharmaceuticals Corporation | 0078-0827 |
| Betoptic Sbetaxolol hydrochloride | Betaxolol hydrochloride 2.8 mg/mL | Suspension/ dropsOphthalmic | Novartis Pharmaceuticals Corporation | 0078-0729 |
| Coartemartemether and lumefantrine | Artemether 20 mg/1; Lumefantrine 120 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0568 |
| Cosentyxsecukinumab | Secukinumab 150 mg/mL | InjectionSubcutaneous | Novartis Pharmaceuticals Corporation | 0078-0639 |
| Cosentyxsecukinumab | Secukinumab 75 mg/.5mL | InjectionSubcutaneous | Novartis Pharmaceuticals Corporation | 0078-1056 |
| Cosentyxsecukinumab | Secukinumab 300 mg/2mL | InjectionSubcutaneous | Novartis Pharmaceuticals Corporation | 0078-1070 |
| Cosentyxsecukinumab | Secukinumab 25 mg/mL | Injection, Solution, ConcentrateIntravenous | Novartis Pharmaceuticals Corporation | 0078-1168 |
| Desferaldeferoxamine mesylate | Deferoxamine mesylate 500 mg/1 | Injection, Powder, Lyophilized, For solutionIntramuscular, Intravenous, Subcutaneous | Novartis Pharmaceuticals Corporation | 0078-0467 |
| Diovanvalsartan | Valsartan 80 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0358 |
| Diovanvalsartan | Valsartan 160 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0359 |
| Diovanvalsartan | Valsartan 320 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0360 |
| Diovanvalsartan | Valsartan 40 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0423 |
| Diovanvalsartan | Valsartan 80 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-1245 |
| Diovanvalsartan | Valsartan 160 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-1252 |
| Diovanvalsartan | Valsartan 320 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-1259 |
| Diovan HCTvalsartan and hydrochlorothiazide | Valsartan 80 mg/1; Hydrochlorothiazide 12.5 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0314 |
| Diovan HCTvalsartan and hydrochlorothiazide | Valsartan 160 mg/1; Hydrochlorothiazide 12.5 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0315 |